Form 4: TVTX Director Sells Shares After Option Exercise

Travere Therapeutics Director Gary A. Lyons exercised stock options and immediately sold 8,000 shares for a profit under a pre-arranged 10b5-1 plan.

Summary

• Gary A. Lyons, a Director of Travere Therapeutics, Inc. (TVTX), executed a pre-planned transaction on April 14, 2026.
• Lyons exercised 8,000 stock options at an exercise price of $16.33 per share.
• Immediately following the exercise, 8,000 shares of common stock were sold at a price of $41.07 per share.
• The sale was conducted under a Rule 10b5-1(c) plan that was adopted on November 11, 2025.
• Following these transactions, Lyons directly owns 57,500 shares of Travere Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It's a routine insider transaction under a pre-planned 10b5-1 schedule, which typically does not signal new material information about the company's prospects.

Positives

• Director Gary A. Lyons realized a significant profit from exercising stock options and selling the shares, indicating personal financial gain.
• The transaction was executed under a pre-arranged 10b5-1 plan, which suggests a planned liquidity event rather than a reaction to new, undisclosed negative information.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived as a lack of confidence in the company's future growth by some investors, though this is often a routine diversification or liquidity event.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common occurrences in the public markets. While a director selling shares might sometimes be viewed negatively, the pre-arranged nature of the sale typically mitigates concerns about it signaling immediate negative company-specific news. Such sales are often for personal financial planning, diversification, or liquidity.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a standard practice for executives and directors to manage their equity holdings while adhering to insider trading regulations.
• The reported transaction reflects the company's stock performance at the time, with the sale price of $41.07 significantly higher than the exercise price of $16.33, indicating a profitable event for the insider.

Related Party Transactions

• The reported transaction involves a director (Gary A. Lyons) of Travere Therapeutics, Inc. selling company stock, which is inherently a related party transaction.

Stakeholder Impact

• Shareholders: May observe the director's sale, but the 10b5-1 plan context generally reduces concerns about negative implications, as it suggests a pre-planned financial event rather than a reaction to new company news.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific insider transaction is indicated.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider sale by a director. While insider selling can sometimes be a negative signal, the execution under a 10b5-1 plan suggests it's for personal financial management rather than a reaction to new, adverse company information. Therefore, it does not provide a strong basis for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

Travere Therapeutics, TVTX, insider trading, Form 4, stock option, share sale, director, 10b5-1 plan, Gary A Lyons, beneficial ownership